Effect of paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in korean diabetic patients

Journal of Interventional Cardiology

Volumn 21, Issue 3, 2008, Pages 225-231

  Kim, Moo Hyun ^a   Hong, Soon Jun ^b   Cha, Kwang Soo ^a   Park, Hun Sik ^c   Chae, Shung Chull ^c   Hur, Seung Ho ^d   Gwon, Hyeon Cheol ^e   Bae, Jang Ho ^f   Lim, Do Sun ^b  

^a Dong A University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

^d Dongsan Medical Center   (South Korea)

^e Samsung Medical Center   (South Korea)

^f Konyang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DIABETIC PATIENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TREATMENT OUTCOME;

AGED; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KOREA; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; RECURRENCE; SIROLIMUS; TREATMENT OUTCOME;

EID: 43949142462     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2008.00353.x     Document Type: Article

References (32)

1. Nishio K, Fukui T, Tsunoda F, et al. Insulin resistance as a predictor for restenosis after coronary stenting. Int J Cardiol 2005 103 : 128 134.
2. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999 48 : 937 942.
3. Przewlocki T, Pieniazek P, Ryniewicz W, et al. Long-term outcome of coronary balloon angioplasty in diabetic patients. Int J Cardiol 2000 76 : 7 16.
4. Wannamethee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart 2004 90 : 1398 1403.
5. Hobbs FD. Reducing cardiovascular risk in diabetes: Beyond glycemic and blood pressure control. Int J Cardiol 2006 110 : 137 145.
6. Waller BF, Palumbo PJ, Lie JT, et al. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years: Analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med 1980 69 : 498 506.
7. Kip KE, Faxon DP, Detre KM, et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996 94 : 1818 1825.
8. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000 355 : 253 259.
9. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 16 : 434 444.
10. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993 22 : 1141 1154.
11. Mick MJ, Piedmonte MR, Arnold AM, et al. Risk stratification for long-term outcome after elective coronary angioplasty: A multivariate analysis of 5,000 patients. J Am Coll Cardiol 1994 24 : 74 80.
12. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995 91 : 979 989.
13. Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: A report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004 109 : 476 480.
14. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998 32 : 1866 1873.
15. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004 350 : 221 231.
16. Holmes DR Jr., Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004 109 : 634 640.
17. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005 353 : 663 670.
18. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome. Circulation 1999 100 : 1872 1878.
19. Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004 109 : 2273 2278.
20. Hermiller JB, Raizner A, Cannon L, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial. J Am Coll Cardiol 2005 45 : 1172 1179.
21. Daemen J, Garcia-Garcia HM, Kukreja N, et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 2007 28 : 26 32.
22. Ong AT, van Domburg RT, Aoki J, et al. Sirolimus-eluting stents remain superior to bare-metal stents at two years: Medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2006 47 : 1356 1360.
23. Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: One-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005 45 : 1135 1141.
24. Schofer J, Schluter M, Rau T, et al. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: A controlled study. J Am Coll Cardiol 2000 35 : 1554 1559.
25. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996 27 : 528 535.
26. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 2002 287 : 2570 2581.
27. Bennett MR. In-stent stenosis: Pathology and implications for the development of drug eluting stents. Heart 2003 89 : 218 224.
28. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003 361 : 247 249.
29. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 345 : 494 502.
30. Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004 27 : 2654 2660.
31. Mazeika P, Prasad N, Bui S, et al. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 2003 145 : 1013 1021.
32. Corpus RA, George PB, House JA, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004 43 : 8 14.